2. Search Result
Search Result
Results for "

Bell's palsy

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Peptides

4

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134850
    QC-01–175

    		PROTACs Tau Protein Neurological Disease
    QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. QC-01-175 reduces the levels of A152T and P301L mutant tau protein and protects neurons from tau-mediated toxicity and improve cell survival (Pink: ligand for target protein Aberrant tau ligand 1 (HY-W453397); Black: linker NH2-PEG3 (HY-W007545); Blue: ligand for E3 ligase Pomalidomide (HY-10984)) .
    QC-01–175
  • HY-P99648
    Gosuranemab

    BMS-986168; IPN007; BIIB092

    		 Tau Protein Neurological Disease
    Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
    Gosuranemab
  • HY-P9995
    Posdinemab

    JNJ-63733657

    		 Tau Protein Neurological Disease
    Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
    Posdinemab
  • HY-122742
    HBT1

    		iGluR Neurological Disease
    HBT1 is an effective AMPA receptor AMPA-R potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) .
    HBT1
  • HY-130452
    NOS1-IN-1

    		NO Synthase Neurological Disease
    NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a Ki of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (Ki=39 μM) and iNOS (Ki=325 μM) , respectively . NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP) .
    NOS1-IN-1
  • HY-107932
    Triamcinolone diacetate

    		Glucocorticoid Receptor Inflammation/Immunology
    Triamcinolone diacetate is a synthetic derivative of glucocorticoid. Triamcinolone diacetate has anti-inflammatory activity. Triamcinolone diacetate can be used in research on dermatomyositis, Bell's palsy and rheumatoid arthritis .
    Triamcinolone diacetate
  • HY-173291
    Tau ligand-1

    		Tau Protein Neurological Disease
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier . In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM . Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system .
    Tau ligand-1
  • HY-P5728
    Aurein 1.1

    		Bacterial Antibiotic Infection
    Aurein 1.1 is an antibiotic peptide that can be found in the Australian Bell Frogs Litoria raniformis .
    Aurein 1.1
  • HY-P5725
    Aurein 2.1

    		Bacterial Antibiotic Infection
    Aurein 2.1 is an antibiotic peptide that can be found in the Australian Bell Frogs Litoria aurea and Litoria raniformis .
    Aurein 2.1
  • HY-P991377
    TBL-100

    		Tau Protein Neurological Disease
    TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
    TBL-100
  • HY-158702
    5-HTQ chloride

    		5-HT Receptor Neurological Disease
    5-HTQ chloride is an indole alkaloid that can be isolated from the skin secretions of the Australian golden bell frog Litoria aurea. 5-HTQ chloride is also a full agonist of the 5-HT receptor .
    5-HTQ chloride
  • HY-172129
    HDAC6-IN-52

    		HDAC Neurological Disease
    HDAC6-IN-52 (EX.1) is a potent inhibitor of HDAC6, with the inhibitory rate of 100% at 10 μM. HDAC6-IN-52 plays an important role in central nervous system diseases including neurodegenerative diseases such as Alzheimer’s disease andprogressive supranuclear palsy .
    HDAC6-IN-52
  • HY-179335
    Aescigenin

    		Others Others
    Aescigenin is a triterpenoid saponin compound that can be found in Aesculus hippocastanum. Aescigenin is the main component of sodium β-aescin, a compound that has the functions of reducing tissue edema, improving microcirculation, and anti-inflammation. It can be used in research on Bell's palsy .
    Aescigenin
  • HY-P99648A
    Gosuranemab (powder)

    BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)

    		 Tau Protein Neurological Disease
    Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
    Gosuranemab (powder)
  • HY-N19726
    Capsianoside IV

    		Drug Derivative Others
    Capsianoside IV is a monomeric acyclic diterpenoid glycoside and geranyl linalool derivative, which can be isolated from the fruits of Capsicum annuum var. grossum (bell pepper) .
    Capsianoside IV
  • HY-181600
    O-GlcNAcase-IN-4

    		OGA Neurological Disease
    O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor with an IC50 of 11.59 nM. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders .
    O-GlcNAcase-IN-4
  • HY-185357
    TAU-IN-6

    		Tau Protein Neurological Disease
    TAU-IN-6 (Compound 13) is a Tau protein misfolding and aggregation inhibitor. TAU-IN-6 inhibits stress granules composed of tau and TIA1. TAU-IN-6 is applicable for Alzheimer's disease research .
    TAU-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: